Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G
Klinik für Innere Medizin III, Universitätskliniken des Saarlandes, Kirrberger Strasse, 66421 Homburg, Germany.
Z Kardiol. 2004 Jan;93(1):43-8. doi: 10.1007/s00392-004-1003-2.
Statins reduce cholesterol and isoprenoid de novo biosynthesis as well as receptor mediated uptake of cholesterol for steroidogenesis. The present randomized placebo-controlled trial investigated whether pravastatin (40 mg/day) reduces the plasma concentrations of steroid hormones as well as of gonadotropins. Patients (n = 22; 15 males, 7 females) were treated with pravastatin (40 mg/day) or placebo. Levels of total and LDL cholesterol, the steroid hormones estradiol, testosterone, cortisol and dehydroepiandrosterone sulphate (DHEAS) as well as FSH and LH were studied. Pravastatin led to a significant reduction of total cholesterol and LDL cholesterol. There was no significant change in estradiol, testosterone, cortisol or DHEAS plasma concentrations. There was no compensatory change in FSH or LH. It is concluded that pravastatin does not alter steroid hormones or gonadotropins in a clinically applicable dose, which significantly reduces total and LDL cholesterol.
他汀类药物可降低胆固醇和类异戊二烯的从头生物合成,以及受体介导的胆固醇摄取以用于类固醇生成。本项随机安慰剂对照试验研究了普伐他汀(40毫克/天)是否会降低甾体激素以及促性腺激素的血浆浓度。患者(n = 22;15名男性,7名女性)接受普伐他汀(40毫克/天)或安慰剂治疗。研究了总胆固醇和低密度脂蛋白胆固醇、甾体激素雌二醇、睾酮、皮质醇和硫酸脱氢表雄酮(DHEAS)以及促卵泡激素和促黄体激素的水平。普伐他汀导致总胆固醇和低密度脂蛋白胆固醇显著降低。雌二醇、睾酮、皮质醇或DHEAS的血浆浓度没有显著变化。促卵泡激素或促黄体激素没有代偿性变化。得出的结论是,普伐他汀在临床适用剂量下不会改变甾体激素或促性腺激素,而该剂量可显著降低总胆固醇和低密度脂蛋白胆固醇。